BNP Paribas Asset Management’s CorMedix CRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.5K Sell
1,334
-225
-14% -$1.78K ﹤0.01% 2219
2026
Q1
$10.6K Buy
1,559
+525
+51% +$3.88K ﹤0.01% 2205
2025
Q4
$12K Buy
1,034
+265
+34% +$2.93K ﹤0.01% 2092
2025
Q3
$9K Buy
769
+169
+28% +$2.04K ﹤0.01% 1660
2025
Q2
$7K Buy
+600
New +$6.62K ﹤0.01% 1883

Other funds holding CRMD

BNP Paribas Asset Management's CRMD Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its CorMedix (CRMD) stake by 14% in Q2 2026, selling an estimated $1.78K and leaving 1,334 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2219.

BNP Paribas Asset Management first reported a position in CRMD in Q2 2025 and has held it in 5 quarters since. The position peaked at $12K in Q4 2025. 193 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • BNP Paribas Asset Management held 1,334 shares of CorMedix worth $10.5K as of Q2 2026.
  • BNP Paribas Asset Management sold 225 CorMedix shares in Q2 2026, an estimated $1.78K.
  • CorMedix made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2219 holding.
  • BNP Paribas Asset Management first reported a position in CorMedix in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's CorMedix position peaked at $12K in Q4 2025.
  • 193 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.